Addition of cytarabine improves outcome for PCNSL patients

Mayo Clinic.jpg

Noting that the prognosis for most patients with primary central nervous system lymphoma is poor regardless of therapy and that only a minority of patients achieve a complete response to current chemotherapy regimens, Mayo Clinic researchers carried out a randomized phase II clinical trial in which high-dose cytarabine was added to high-dose methotrexate .

According to their findings, published in Nature Reviews Clinical Oncology, the regimen both increased the complete response rate and improved patient outcome.

By Ross Bonander

Source: Hematology: Trials and tribulations in primary CNS lymphoma

LymphomaInfo Social